Abstract
Abdominal aortic aneurysm (AAA) is a common aortic disease with a progressive nature. There is no approved pharmacological treatment that would effectively slow the growth of the aneurysm or prevent rupture. Necrosis is a form of programmed necrosis that is regulated by receptor-interacting protein kinases (RIPs). We have recently shown that a lack of RIP3 in mice prevented aneurysm formation.
The aim of this study is to test whether disruptive necrosis affects the progression of existing aneurysms using RIP1 inhibitors Necrostatin-1 (Nec-1) and optimized forms of Nec-1, 7-Cl-O-Nec-1 (Nec-1 s). Seven days after induction of the aneurysm by elastase perfusion, mice were randomly administered DMSO, Nec-1 (3.2 mg / kg / day) and Nec-1s (1.6 mg / kg / day) by intraperitoneal injection. After sacrifice on day 14 of postaneurysm induction, the aortic expansion in the Nec-1s group (64.12 ± 4.80%) was significantly smaller than in the DMSO group (172.80 ± 13.68%) (P <0.05).
Product Details:
| Alternate Name | 5-((7-Cl-1H-indol-3-yl)methyl)-3-methylimidazolidine-2,4-dione); 7-Cl-O-Nec-1 |
|---|
| Peptide Sequence | No |
|---|
| Appearance | Yellow solid |
|---|
| CAS # | 852391-15-2 |
|---|
| Molecular Formula | C₁₃H₁₂ClN₃O₂ |
|---|
| Molecular Weight | 277.71 |
|---|
| Purity | ≥96% by TLC and LC-MS |
|---|
| Solubility | DMSO |
|---|
| SMILES | CN1C(=O)C(NC1=O)CC2=CNC3=C2C=CC=C3Cl |
|---|
| InChi | InChI=1S/C13H12ClN3O2/c1-17-12(18)10(16-13(17)19)5-7-6-15-11-8(7)3-2-4-9(11)14/h2-4,6,10,15H,5H2,1H3,(H,16,19) |
|---|
| InChi Key | WIKGAEMMNQTUGL-UHFFFAOYSA-N |
|---|
| PubChem CID | 643953 |
|---|
| Handling | Protect from light and moisture |
|---|
| Storage Conditions | -20°C |
|---|
| Shipping Conditions | Gel Pack |
|---|
| USAGE | For Research Use Only! Not For Use in Humans. |
|---|
biovision nec 1s
Descriptions:
A potent necroptosis inhibitor. Displays higher activity in inhibiting necroptosis in Jurkat cells than Nec-1 (Cat. No. 1864) (EC₅₀ = 210 nM versus EC₅₀ = 490 nM), as well as showing no nonspecific cytotoxicity at high concentrations (~100 mM). More useful for in-cell and in vivo experiments compared to Nec-1.
The mean aortic diameter of Nec-1-treated mice appeared to be smaller (121.60 ± 10.40%) than the DMSO group, although the difference was not statistically significant (P = 0.1). Histologically, the aortic structure of Nec-1s-treated mice appeared normal, with continuous and organized elastin layers and rich SMCs expressing αActin. In addition, Nect-1 treatment reduced macrophage infiltration and MMP9 accumulation and increased tropoelastin and lysyl oxidase aortic levels. Together, our data suggest that pharmacological inhibition of necrosis by Nec-1 stabilizes pre-existing aneurysms by reducing inflammation and promoting connective tissue repair.
 Nec-4 |
| HY-18900 | MedChemExpress | Get quote | Ask for price |
Description: Nec-4, a tricyclic derivative, is a potent receptor interacting protein 1 (RIP1) inhibitor, with an IC50 of 2.6 μM, Ki of 0.46 μM. |
 Nec-3a |
| HY-18899 | MedChemExpress | Get quote | Ask for price |
Description: Nec-3a is a Necrostatin-3 analogue. Nec-3a is a RIP1 inhibitor (IC50: 0.44 μM). Nec-3a inhibits the autophosphorylation activity of the RIP1 kinase domain[1]. |
) Necrostatin-7 (Nec-7) |
| MBS6031043-5mg | MyBiosource | 5(mg | EUR 395 |
Necrostatin-7 (Nec-7) |
| MBS6031043-5x5mg | MyBiosource | 5x5(mg | EUR 1620 |
 7-CL-O-Nec-1 |
| MBS516410-5x25mg | MyBiosource | 5x25mg | EUR 1835 |
 NOMO-1s |
| ABL-TC0480 | AcceGen | 1 vial | Ask for price |
Description: NOMO-1s Cell Line is from human; Tissue: hemo-lymphocytic; Morphology: round; Profile: This cell line is useful for studying the differentiation and maturation of monocytes. |
 IQ-1S |
| abx282388-100g | Abbexa | 100 µg | Ask for price |
IQ-1S |
| abx282388-20g | Abbexa | 20 µg | EUR 118.75 |
IQ-1S |
| abx282388-50g | Abbexa | 50 µg | EUR 225 |
-Chrysanthemolactone) (1S)-Chrysanthemolactone |
| TN2671-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: (1S)-Chrysanthemolactone |
(1S)-Chrysanthemolactone |
| TN2671-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: (1S)-Chrysanthemolactone |
(1S)-Chrysanthemolactone |
| TN2671-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: (1S)-Chrysanthemolactone |
(1S)-Chrysanthemolactone |
| TN2671-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: (1S)-Chrysanthemolactone |
(1S)-Chrysanthemolactone |
| TN2671-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: (1S)-Chrysanthemolactone |
 MM.1S |
| CSC-C9219W | Creative Bioarray | One Frozen vial | Ask for price |
Description: Leukemia - Lymphoma - Myeloma Cells |
-Calcitriol) (1S)-Calcitriol |
| MBS5796866-1mg | MyBiosource | 1(mg | EUR 1480 |
(1S)-Calcitriol |
| MBS5796866-5x1mg | MyBiosource | 5x1(mg | EUR 6510 |
-Camphorsultam) (1S)-Camphorsultam |
| MBS6114899-1g | MyBiosource | 1(g | EUR 485 |
(1S)-Camphorsultam |
| MBS6114899-5x1g | MyBiosource | 5x1g | EUR 2025 |
-(+)-Myrtenol)